China – s Drug-Price Cuts Are Hitting Big Pharma Where It Hurts #anabolic #pharma

Posted On Dec 27 2017 by

#chinese pharmaceutical companies # China’s Drug-Price Cuts Are Hitting Big Pharma Where It Hurts The world’s largest pharmaceutical companies are facing a roadblock in China as a state-led campaign to slash drug prices has triggered a slowdown in sales growth. One of the biggest problems: China’s government-run health insurance funds, which are struggling to keep up with an ageing population and surging incidence of diseases like cancer or diabetes. As they grapple with tighter budgets and a slowing economy, many of these funds are capping reimbursements to patients and pushing local authorities to negotiate with companies to lower drug prices. …


China – s Drug-Price Cuts Are Hitting Big Pharma Where It Hurts #pharma #bio

Posted On Dec 2 2017 by

#chinese pharmaceutical companies # China’s Drug-Price Cuts Are Hitting Big Pharma Where It Hurts The world’s largest pharmaceutical companies are facing a roadblock in China as a state-led campaign to slash drug prices has triggered a slowdown in sales growth. One of the biggest problems: China’s government-run health insurance funds, which are struggling to keep up with an ageing population and surging incidence of diseases like cancer or diabetes. As they grapple with tighter budgets and a slowing economy, many of these funds are capping reimbursements to patients and pushing local authorities to negotiate with companies to lower drug prices. …


UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ #pharmaceutical #companies #market #share

Posted On Nov 13 2017 by

#sankyo pharma # UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ Times have been tough for Daiichi Sankyo, and they’re about to get tougher for some of the Japanese company’s U.S. staffers. The drugmaker is cutting its commercial headquarters staff by 16% on Monday, with more layoffs expected in mid-April. The cutbacks are part of a revamp at Daiichi’s U.S. business, based in Parsippany, NJ. The reasons for cutbacks are clear: Daiichi’s exclusivity on the cholesterol drug Welchol expires in June, and a bigger product–the blood pressure drug Benicar–loses its lock on the market next year. That …


China – s Drug-Price Cuts Are Hitting Big Pharma Where It Hurts #pharma #test

Posted On Nov 8 2017 by

#chinese pharmaceutical companies # China’s Drug-Price Cuts Are Hitting Big Pharma Where It Hurts The world’s largest pharmaceutical companies are facing a roadblock in China as a state-led campaign to slash drug prices has triggered a slowdown in sales growth. One of the biggest problems: China’s government-run health insurance funds, which are struggling to keep up with an ageing population and surging incidence of diseases like cancer or diabetes. As they grapple with tighter budgets and a slowing economy, many of these funds are capping reimbursements to patients and pushing local authorities to negotiate with companies to lower drug prices. …


UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ #pharma #regulatory

Posted On Sep 30 2017 by

#sankyo pharma # UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ Times have been tough for Daiichi Sankyo, and they’re about to get tougher for some of the Japanese company’s U.S. staffers. The drugmaker is cutting its commercial headquarters staff by 16% on Monday, with more layoffs expected in mid-April. The cutbacks are part of a revamp at Daiichi’s U.S. business, based in Parsippany, NJ. The reasons for cutbacks are clear: Daiichi’s exclusivity on the cholesterol drug Welchol expires in June, and a bigger product–the blood pressure drug Benicar–loses its lock on the market next year. That …


China – s Drug-Price Cuts Are Hitting Big Pharma Where It Hurts #french #pharmaceutical #companies

Posted On Sep 9 2017 by

#chinese pharmaceutical companies # China’s Drug-Price Cuts Are Hitting Big Pharma Where It Hurts The world’s largest pharmaceutical companies are facing a roadblock in China as a state-led campaign to slash drug prices has triggered a slowdown in sales growth. One of the biggest problems: China’s government-run health insurance funds, which are struggling to keep up with an ageing population and surging incidence of diseases like cancer or diabetes. As they grapple with tighter budgets and a slowing economy, many of these funds are capping reimbursements to patients and pushing local authorities to negotiate with companies to lower drug prices. …


UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ #mayne #pharma

Posted On Aug 14 2017 by

#sankyo pharma # UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ Times have been tough for Daiichi Sankyo, and they’re about to get tougher for some of the Japanese company’s U.S. staffers. The drugmaker is cutting its commercial headquarters staff by 16% on Monday, with more layoffs expected in mid-April. The cutbacks are part of a revamp at Daiichi’s U.S. business, based in Parsippany, NJ. The reasons for cutbacks are clear: Daiichi’s exclusivity on the cholesterol drug Welchol expires in June, and a bigger product–the blood pressure drug Benicar–loses its lock on the market next year. That …


UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ #top #50 #pharmaceutical #companies

Posted On May 28 2017 by

#sankyo pharma # UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ Times have been tough for Daiichi Sankyo, and they’re about to get tougher for some of the Japanese company’s U.S. staffers. The drugmaker is cutting its commercial headquarters staff by 16% on Monday, with more layoffs expected in mid-April. The cutbacks are part of a revamp at Daiichi’s U.S. business, based in Parsippany, NJ. The reasons for cutbacks are clear: Daiichi’s exclusivity on the cholesterol drug Welchol expires in June, and a bigger product–the blood pressure drug Benicar–loses its lock on the market next year. That …


China – s Drug-Price Cuts Are Hitting Big Pharma Where It Hurts #spectrum #pharma

Posted On May 17 2017 by

#chinese pharmaceutical companies # China’s Drug-Price Cuts Are Hitting Big Pharma Where It Hurts The world’s largest pharmaceutical companies are facing a roadblock in China as a state-led campaign to slash drug prices has triggered a slowdown in sales growth. One of the biggest problems: China’s government-run health insurance funds, which are struggling to keep up with an ageing population and surging incidence of diseases like cancer or diabetes. As they grapple with tighter budgets and a slowing economy, many of these funds are capping reimbursements to patients and pushing local authorities to negotiate with companies to lower drug prices. …


UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ #global #pharmaceutical #industry

Posted On May 13 2017 by

#sankyo pharma # UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ Times have been tough for Daiichi Sankyo, and they’re about to get tougher for some of the Japanese company’s U.S. staffers. The drugmaker is cutting its commercial headquarters staff by 16% on Monday, with more layoffs expected in mid-April. The cutbacks are part of a revamp at Daiichi’s U.S. business, based in Parsippany, NJ. The reasons for cutbacks are clear: Daiichi’s exclusivity on the cholesterol drug Welchol expires in June, and a bigger product–the blood pressure drug Benicar–loses its lock on the market next year. That …